



GOVERNMENT OF NEPAL

1748, Madan Bhandari Path-4  
Bijuli Bazar, Kathmandu

MINISTRY OF HEALTH AND POPULATION  
DEPARTMENT OF DRUG ADMINISTRATION



Ref. No.: 3555


Date: 29<sup>th</sup> March, 2019

M/s Bafna Pharmaceuticals Pvt. Ltd,  
Chennai, India.

**Subject: Report on GMP Audit**

Based on the inspection (dated July 17, 2018) conducted by the audit team at your facility located at Chennai, India, we are pleased to inform you that your manufacturing site satisfies the requirements of WHO GMP guidelines for **General products (tablets and capsules)**.

We appreciate your interest to register and market products in Nepal. The audit report is attached herewith for your notice and necessary improvement.

  
.....  
Narayan Prasad Dhakal  
Director General  
**Director General**

C.C

1. M/s Registration Division, Department of Drug Administration.
2. M/s Sijal Pharma Pvt. Ltd.